Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Disease Progression × umbralisib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 12 Lymphoma, Non-Hodgkin 5 Lymphoma, Follicular 3 Lymphoma, Mantle-Cell 2 Hodgkin Disease 2 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell, Marginal Zone 1 Disease Progression 1

Interventions

umbralisib 1 ublituximab 1 brigatinib 1 binimetinib 1 Zoledronic Acid 1 Vitamin D 1 Irinotecan 1 Calcium 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04149821 2023-06-15

Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Weill Medical College of Cornell University

Phase 2 Terminated

1 enrolled 8 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡